Home › NCT04787471

Corneal Crosslinking for Treatment of Corneal Neovascularization

Randomized Comparison of Standard vs. Accelerated Corneal Crosslinking for Treatment of Corneal Neovascularization With or Without Concomitant Inflammation and/or Infection

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* 18 years of age or older
* With active inflammation or infection causing vascularization and possibly melting of the cornea, or vessels extending into the cornea causing lipid deposition, or vascularization that could significantly increase the risk of rejection of a current or planned corneal transplant, or vessels that continue to extend into the cornea despite topical treatment with corticosteroids.
* Signed written informed consent.

Exclusion Criteria:

* Known sensitivity to treatment medications
* Current condition that in the investigator's opinion could compromise safety or data integrity.
* Pregnancy (including plan to become pregnant) or lactation during the course of the study

About the study

The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.

What is being tested

• 30 minute photoactivation of riboflavin 0.1% (combination product)
• 10 minute photoactivation of riboflavin 0.1% (combination product)

Sponsor: Price Vision Group · Participants: 138 · Started: May 3, 2021

Contact the study team

• Marianne Price, PhD · Phone: 317-814-2990

Official record on ClinicalTrials.gov — NCT04787471

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.